Figure 4.

Breakthrough infection in vaccinated LA-SPARTA participants is more prevalent in Hispanic participants. (A) shows the change in RBD, Spike, and NP concentration between the reported and serologically detected breakthrough infections at the prior blood sample before the breakthrough infection was either reported or detected and after. (B) shows the distribution of risk category in the participants with breakthrough infections by number (left) and percentage (right). (C) An interval-censored regression model was used to compare the hazard ratios for breakthrough infection between Hispanic and Non-Hispanic participants. The Kaplan Meier curve is shown to represent this analysis. (D) shows the decay rate for antibodies against both RBD and Spike proteins on the log scale between Hispanic and non-Hispanic vaccinated participants. Panel (E) shows the piecewise linear regression model to find times at which the slopes of raw values change among Hispanic (left plot) and non-Hispanic participants (right plot). This analysis included 65 Hispanic participants, who contributed 95 samples and 93 non-Hispanic participants, who contributed 148 samples to the analysis. (F) shows the concentration of RBD, Spike, and NP after roughly 1-4 months after vaccination, in participants who had breakthrough infection later in the study and control participants who did not have breakthrough infection. (G) shows the concentration of RBD and NP after roughly 1-4 months after vaccination, in participants who had breakthrough infection later in the study according to ethnicity.* designates P >0.05, ** designates P >0.01, *** designates P >0.001, and **** designates P >0.0001. ns, not significant.